Nkarta, Inc. (NASDAQ:NKTX) Receives $15.00 Average Price Target from Brokerages

Shares of Nkarta, Inc. (NASDAQ:NKTX) have been assigned an average rating of “Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $15.00.

Several equities analysts recently weighed in on the stock. Mizuho reduced their target price on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a report on Thursday, November 21st. Needham & Company LLC reduced their target price on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Finally, HC Wainwright reduced their target price on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, November 11th.

Nkarta Stock Up 4.2 %

Shares of NKTX opened at $2.21 on Tuesday. The firm has a market cap of $155.96 million, a PE ratio of -1.18 and a beta of 0.85. The company’s fifty day moving average is $2.35 and its two-hundred day moving average is $3.62. Nkarta has a fifty-two week low of $1.96 and a fifty-two week high of $16.24.

Insider Buying and Selling

In related news, CEO Paul J. Hastings sold 17,378 shares of Nkarta stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the sale, the chief executive officer now owns 319,859 shares of the company’s stock, valued at $703,689.80. The trade was a 5.15 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 8.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Nkarta

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its stake in Nkarta by 41.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company’s stock worth $60,000 after buying an additional 7,030 shares during the period. Hsbc Holdings PLC increased its stake in Nkarta by 102.8% during the 4th quarter. Hsbc Holdings PLC now owns 73,845 shares of the company’s stock worth $171,000 after buying an additional 37,433 shares during the period. Stifel Financial Corp increased its stake in Nkarta by 11.5% during the 4th quarter. Stifel Financial Corp now owns 90,811 shares of the company’s stock worth $226,000 after buying an additional 9,359 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Nkarta by 101.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 569,357 shares of the company’s stock worth $1,417,000 after purchasing an additional 286,181 shares during the last quarter. Finally, Wasatch Advisors LP increased its position in shares of Nkarta by 37.4% in the 4th quarter. Wasatch Advisors LP now owns 2,520,909 shares of the company’s stock worth $6,277,000 after purchasing an additional 686,229 shares during the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.